[go: up one dir, main page]

ATE473961T1 - Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung - Google Patents

Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung

Info

Publication number
ATE473961T1
ATE473961T1 AT06850138T AT06850138T ATE473961T1 AT E473961 T1 ATE473961 T1 AT E473961T1 AT 06850138 T AT06850138 T AT 06850138T AT 06850138 T AT06850138 T AT 06850138T AT E473961 T1 ATE473961 T1 AT E473961T1
Authority
AT
Austria
Prior art keywords
glucagon receptor
preparation
receptor antagonists
therapeutic use
compounds
Prior art date
Application number
AT06850138T
Other languages
English (en)
Inventor
Mark Chappell
Scott Conner
Philip Hipskind
Jason Lamar
Guoxin Zhu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE473961T1 publication Critical patent/ATE473961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT06850138T 2005-11-18 2006-11-10 Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung ATE473961T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73797905P 2005-11-18 2005-11-18
PCT/US2006/060769 WO2007114855A2 (en) 2005-11-18 2006-11-10 Glucagon receptor antagonists, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
ATE473961T1 true ATE473961T1 (de) 2010-07-15

Family

ID=38470878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850138T ATE473961T1 (de) 2005-11-18 2006-11-10 Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung

Country Status (12)

Country Link
US (1) US8076374B2 (de)
JP (1) JP5100657B2 (de)
CN (1) CN101309894B (de)
AT (1) ATE473961T1 (de)
AU (1) AU2006341392B2 (de)
BR (1) BRPI0618484A2 (de)
CA (1) CA2629321C (de)
DE (1) DE602006015509D1 (de)
DK (1) DK1951659T3 (de)
ES (1) ES2346246T3 (de)
PT (1) PT1951659E (de)
WO (1) WO2007114855A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569459C (en) * 2004-06-14 2013-01-29 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
KR20180099916A (ko) 2007-02-09 2018-09-05 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
KR101599089B1 (ko) 2008-08-13 2016-03-02 메타베이시스 테라퓨틱스, 인크. 글루카곤 길항제
AU2009298617A1 (en) 2008-10-03 2010-04-08 Schering Corporation Spiro-imidazolone derivatives as glucagon receptor antagonists
EP2480077B1 (de) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidine als glucagonrezeptorantagonisten, zusammensetzungen daraus und verfahren zu ihrer verwendung
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
HUE030364T2 (hu) * 2011-02-08 2017-04-28 Pfizer Glukagonreceptor modulátora
WO2013014569A1 (en) * 2011-07-22 2013-01-31 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
US10201617B2 (en) 2014-10-24 2019-02-12 Zhuhai Beihai Biotech Co., Ltd. 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
US12208071B2 (en) 2018-02-13 2025-01-28 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
EP1519723A1 (de) 2002-06-27 2005-04-06 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
AU2003291959A1 (en) * 2002-12-20 2004-07-14 Novo Nordisk A/S Novel glucagon antagonists
WO2004063147A1 (en) * 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
EP1740058A1 (de) 2004-04-26 2007-01-10 Ipn Ip B.V. Verpacktes, fliessfähiges eisprodukt, wie zum beispiel ein milch-shake

Also Published As

Publication number Publication date
US8076374B2 (en) 2011-12-13
AU2006341392B2 (en) 2012-05-17
CA2629321C (en) 2013-08-06
ES2346246T3 (es) 2010-10-13
JP2009519227A (ja) 2009-05-14
CN101309894A (zh) 2008-11-19
BRPI0618484A2 (pt) 2011-08-30
DK1951659T3 (da) 2010-10-11
CA2629321A1 (en) 2007-10-11
JP5100657B2 (ja) 2012-12-19
US20080319074A1 (en) 2008-12-25
WO2007114855A2 (en) 2007-10-11
WO2007114855A3 (en) 2007-11-29
CN101309894B (zh) 2012-10-03
DE602006015509D1 (de) 2010-08-26
AU2006341392A1 (en) 2007-10-11
PT1951659E (pt) 2010-09-10

Similar Documents

Publication Publication Date Title
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
NO20070213L (no) Glucagon reseptorantagonister, fremstilling og terapeutiske anvendelser
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
DK1735278T3 (da) Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
ATE523488T1 (de) Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951659

Country of ref document: EP